From 2016 to 2021, a decreasing trend of susceptibility of E. coli was observed for imipenem (85.9% to 64%), meropenem (80.7% to 695%), ceftazidime (25% to 18%), ciprofloxacin (20.3% to 19%), and amikacin (83.8% to 78.2%) ( Inda-Díaz et al., 2023 ).
← all excerpts
Antimicrobial resistance burden, and mechanisms of its emergence in gut microbiomes of Indian population.
1
—
—